EX-99.1 2 ex99-1.htm EX-99.1

NEWS RELEASE
   
  CONTACT:
  CONMED Corporation
  Robert Shallish
  Chief Financial Officer
  315-624-3206
   
  FTI Consulting
  Investors:  Brian Ritchie
  212-850-5600

 

 

FOR RELEASE: 7:00 AM (Eastern) July 26, 2012

 

CONMED Corporation Announces Second Quarter 2012 Financial Results

 

- Sales Increase 3.5%

- GAAP EPS Increases 20%

- Adjusted EPS Increases 23%

- Conference Call to be Held at 10:00 a.m. ET Today -

 

 

Utica, New York, July 26, 2012 ----- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the second quarter ended June 30, 2012.

 

“CONMED delivered strong earnings and generated solid cash flow during the second quarter,” commented Mr. Joseph J. Corasanti, President and CEO. “Earnings per share grew 20% and adjusted earnings per share increased 23% on overall sales growth of 3.5%. Single-use products continued their momentum from the first quarter, achieving overall revenue growth of 7.5%. Moreover, we continue to improve our operating and EBITDA margin metrics.”

 

As discussed below under “Use of Non-GAAP Financial Measures,” the Company presents various non-GAAP adjusted financial measures in this release. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with generally accepted accounting principles (“GAAP”). Please refer to the attached reconciliation between GAAP and adjusted financial measures.

 

Second Quarter 2012 Financial Highlights:

 

·Sales grew to $189.7 million, an increase of 3.5% (organic decline of 0.4%).

 

·Single-use products comprised 81.1% of total revenues and grew 7.5%, while sales of capital products declined 10.7%.

 

·Diluted earnings per share (GAAP) grew 20.0% to $0.36.

 

·Adjusted diluted earnings per share grew 22.9% to $0.43.

 

·Adjusted operating margin expanded 90 basis points to 10.6%.

 

 
 

 

CONMED News Release Continued Page 2 of 13 July 26, 2012

  

·GAAP operating margin was 9.0%.

 

·Adjusted EBITDA margin expanded 160 basis points to 16.4%.

 

·GAAP EBITDA margin operating margin was 14.8%.

 

·The Board of Directors continued the cash dividend policy and declared the second quarterly dividend of $0.15 per share, which was paid on July 6, 2012.

 

Six Months 2012 Financial Highlights

 

·Sales grew to $384.0 million, an increase of 4.7% (increase of 0.7% organic).

 

·Single-use products comprised 80.3% of total revenues and grew 8.3%, while capital products declined 7.6%.

 

·Diluted earnings per share (GAAP) grew 16.4% to $0.71

 

·Adjusted earnings per share grew 18.1% to $0.85

 

·Adjusted operating margin expanded 60 basis points to 10.6%.

 

·GAAP operating margin was 8.9%.

 

·Adjusted EBITDA margin expanded 160 basis points to 16.5%.

 

·GAAP EBITDA margin was 14.8%

 

International sales in the second quarter and first half of 2012 were $96.4 million and $194.6 million, respectively, slightly more than 50.0% of total sales. The recent volatility in foreign currency exchange rates was mitigated by the Company’s currency hedging. Net of the hedges, foreign currency exchange rates were approximately the same in 2012 as those of 2011.

 

Cash provided by operating activities in the second quarter of 2012 increased from the prior year period and amounted to $25.6 million. For the six months ended June 2012, cash provided by operating activities totaled $33.3 million. As previously disclosed, cash flow in the first quarter of 2012 was affected by a contribution of $6.5 million to the Company’s frozen pension plan and payment of incentive compensation.

 

Outlook

 

“CONMED has demonstrated superior earnings and cash flow in the first half of 2012 and we expect to continue these trends in the second half of the year,” continued Mr. Corasanti. "Therefore, we are reiterating the previously provided full year 2012 earnings guidance of adjusted earnings per share of $1.75 - $1.85. As to the top-line, while single use product sales continue to be strong, capital product sales in the first half of 2012 were lower than anticipated due to lingering global economic headwinds. Accordingly, the sales forecast for 2012 has been revised to $765 - $775 million from $775 - $785 million.”

 

“For the third quarter of 2012, we anticipate sales will approximate $180 - $185 million and adjusted earnings per share are forecasted to be $0.38 - $0.42,” noted Mr. Corasanti.

 

The sales and earnings forecasts have been developed using June 2012 currency exchange rates and take into account the currency hedges entered into by the Company. CONMED estimates that 80% of the currency exposure is hedged for 2012 at the following average annual exchange rates: Euro - $1.41, CAD - $1.00, GPB - $1.60 and AUD - $1.00.

 

 
 

 

CONMED News Release Continued Page 3 of 13 July 26, 2012

 

The adjusted estimates for the second quarter and full year 2012 exclude unusual matters, such as the manufacturing restructuring costs expected to be incurred in 2012 due to the relocation of manufacturing activities from the Santa Barbara, California site to the Company’s facilities in Chihuahua, Mexico and Largo, Florida. Marketing and R&D activities will remain in Santa Barbara, as previously disclosed. Additionally, the Company has announced the consolidation of the Tampere, Finland location into United States facilities. The consolidation will occur over the next twelve months and costs related to this consolidation are excluded from the estimates above.

 

Association with The Musculoskeletal Transplant Foundation

 

On January 3, 2012, CONMED became the exclusive world-wide marketing representative of MTF’s sports medicine allograft tissues. In accordance with MTF’s commitment to the stewardship of the donated gift, the organization maintains full responsibility for all activities related to donor suitability, quality acceptance, processing, storage, and distribution of the tissue, as well as reimbursement of service fees related to the sports medicine allografts. CONMED’s team of surgical representatives serves as the educational resource to surgeons and facilities concerning the suitability of MTF allografts for ligament reconstruction, cartilage repair and meniscal transplantation, as well as for biologic solutions, including scaffolds and fixation devices. MTF will share 50% of the service revenue with CONMED for these educational activities.

 

Upon signing of the agreement, CONMED paid $63 million to MTF. The agreement calls for additional consideration to be paid to MTF of $84 million over the next four years contingent upon MTF providing an adequate supply of tissue. We have recorded the full amount of the consideration as a long term asset and amortize this amount ratably over the 25 year life of the agreement. Remaining contingent payments to MTF have been recorded as other liabilities. Revenues from the MTF association amounted to $7.2 million in the second quarter of 2012 and $14.7 million for the first six month of 2012.

 

Unusual charges

 

During the first half of 2012, the Company continued the on-going consolidation of certain administrative functions and the transfer of additional product lines to its Mexican manufacturing facility and began the consolidation of the Tampere facility. Also incurred were integration costs relative to the purchase of a distributor in northern Europe and litigation costs associated with a contractual dispute with a former distributor. Expenses associated with these activities, including severance and relocation costs, amounted to $1.9 million, net of tax, in the second quarter of 2012 and $4.1 million net of tax for the six months. These charges are included in the GAAP earnings per share set forth above and are excluded from the adjusted results. For the remainder of 2012, the Company presently anticipates incurring additional pre-tax restructuring costs of $5.0 - $6.0 million on projects currently in process.

  

Use of non-GAAP financial measures

 

Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company’s on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income and adjusted earnings per share measure the income of the Company excluding unusual credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Management uses and presents adjusted net income and adjusted earnings per share because management believes that in order to properly understand the Company’s short and long-term financial trends, the impact of unusual items should be eliminated from on-going operating activities. These adjustments for unusual items are derived from facts and circumstances that vary in frequency and impact on the Company’s results of operations. Management uses adjusted net income and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

 

 
 

 

CONMED News Release Continued Page 4 of 13 July 26, 2012

  

Conference call

 

The Company will webcast its second quarter 2012 conference call live over the Internet at 10:00 a.m. Eastern Time on Thursday, July 26, 2012. This webcast can be accessed from CONMED’s web site at www.conmed.com. Replays of the call will be made available through August 5, 2012.

 

 

CONMED profile

 

CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures and patient monitoring. The Company’s products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery and endoscopic technologies. They are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company’s 3,400 employees distribute its products worldwide from several manufacturing locations.

 

Forward Looking Information

 

This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw materials or transportation (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company’s ability to devise and execute strategies to respond to market conditions.

 
 

 

CONMED News Release Continued Page 5 of 13 July 26, 2012

  

CONMED CORPORATION

CONSOLIDATED STATEMENTS OF INCOME

(in thousands except per share amounts)

(unaudited)

 

   Three months ended  Six months ended
   June 30,  June 30,
   2011  2012  2011  2012
             
Net sales  $183,236   $189,695   $366,686   $384,011 
                     
Cost of sales   90,795    88,761    177,775    180,692 
Cost of sales, other – Note A   986    1,202    1,740    2,676 
                     
Gross profit   91,455    99,732    187,171    200,643 
                     
Selling and administrative   67,862    73,707    137,940    148,513 
Research and development   6,797    7,192    14,478    14,287 
Other expense– Note B   98    1,775    792    3,763 
    74,757    82,674    153,210    166,563 
                     
Income from operations   16,698    17,058    33,961    34,080 
                     
Amortization of debt discount   1,113    —    2,207    — 
                     
Interest expense   1,707    1,551    3,512    2,988 
                     
Income before income taxes   13,878    15,507    28,242    31,092 
                     
Provision for income taxes   5,198    5,211    10,567    10,828 
                     
Net income  $8,680   $10,296   $17,675   $20,264 
                     
Per share data:                    
                     
Net Income                    
Basic  $.31   $.36   $.62   $.72 
Diluted   .30    .36    .61    .71 
                     
Weighted average common shares                    
Basic   28,448    28,327    28,356    28,178 
Diluted   28,883    28,672    28,820    28,577 

 

Note A –Included in cost of sales, other in the three and six months ended June 30, 2011 are $1.0 million and $1.7 million, respectively, related to the consolidation of our production facilities. For the three and six months ending June 30, 2012, we incurred $1.2 million and $2.7 million, respectively, related to the consolidation of our production facilities.

 

Note B –Included in other expense in the three and six months ended June 30, 2011 are $0.1 million and $0.8 million, respectively, related to consolidating certain administrative functions at our Utica, New York facility. For the three and six months ending June 30, 2012, we incurred $1.2 million and $1.5 million, respectively, related to administrative consolidation expense. Also included in other expense in the three and six months ending June 30, 2012 are $0.5 million and $1.6 million, respectively, in legal costs associated with a contractual dispute with a former distributor. Included in the six months ending June 30, 2012 is $0.7 million in costs associated with the acquisition of our former distributor in the Nordic region of Europe.

 

 
 

 

CONMED News Release Continued Page 6 of 13 July 26, 2012

 

 

CONMED CORPORATION

CONSOLIDATED CONDENSED BALANCE SHEETS

(in thousands)

(unaudited)

ASSETS

 

   December 31,  June 30,
   2011  2012
Current assets:          
Cash and cash equivalents  $26,048   $16,246 
Accounts receivable, net   135,641    136,095 
Inventories   168,438    159,151 
Deferred income taxes   10,283    10,906 
Other current assets   16,314    15,037 
Total current assets   356,724    337,435 
           
Property, plant and equipment, net   139,187    140,844 
Deferred income taxes   2,389    2,443 
Goodwill   234,815    234,839 
Other intangible assets, net   195,531    191,741 
Other assets   6,948    153,929 
Total assets  $935,594   $1,061,231 
           
LIABILITIES AND SHAREHOLDERS' EQUITY
           
Current liabilities:          
Current portion of long-term debt  $54,557   $22,534 
Other current liabilities   76,627    112,713 
Total current liabilities   131,184    135,247 
           
Long-term debt   88,952    145,437 
Deferred income taxes   92,785    99,417 
Other long-term liabilities   49,602    87,747 
Total liabilities   362,523    467,848 
           
Shareholders' equity:          
Capital accounts   244,980    255,044 
Retained earnings   354,439    366,219 
Accumulated other comprehensive loss   (26,348)   (27,880)
Total shareholders’ equity   573,071    593,383 
           
Total liabilities and shareholders' equity  $935,594   $1,061,231 

 

 

 
 

 

CONMED News Release Continued Page 7 of 13 July 26, 2012

 

 

CONMED CORPORATION

CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

 

   Six months ended
   June 30,
   2011  2012
Cash flows from operating activities:          
Net income  $17,675   $20,264 
Adjustments to reconcile net income          
to net cash provided by operating activities:          
Depreciation and amortization   21,047    23,064 
Stock-based compensation expense   2,232    2,574 
Deferred income taxes   8,981    6,091 
Increase (decrease) in cash flows from changes in assets and liabilities:          
Accounts receivable   (4,541)   (1,027)
Inventories   78    3,078 
Accounts payable   2,309    1,345 
Income taxes payable   143    (4,589)
Accrued compensation and benefits   (5,684)   (6,730)
Other assets   (2,226)   (1,779)
Other liabilities   209    (9,014)
Net cash provided by operating activities   40,223    33,277 
           
Cash flows from investing activities:          
Purchases of property, plant, and equipment   (8,576)   (11,596)
Payments related to business acquisitions and distribution agreement   (72)   (64,116)
Net cash used in investing activities   (8,648)   (75,712)
           
Cash flows from financing activities:          
Payments on debt   (23,113)   (32,538)
Proceeds from debt   —    57,000 
Dividend payments from common stock   —    (4,328)
Net proceeds from common stock issued under employee plans   5,495    7,868 
Other, net   (3,148)   4,925 
Net cash provided by (used in) financing activities   (20,766)   32,927 
           
Effect of exchange rate change          
on cash and cash equivalents   1,105    (294)
           
Net increase (decrease) in cash and cash equivalents   11,914    (9,802)
           
Cash and cash equivalents at beginning of period   12,417    26,048 
           
Cash and cash equivalents at end of period  $24,331   $16,246 

 

 
 

 

CONMED News Release Continued Page 8 of 13 July 26, 2012

CONMED CORPORATION

RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME

BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT

Three Months Ended June 30, 2011 and 2012

(in thousands except per share amounts)

(unaudited)

 

   2011  2012
       
Reported net income  $8,680   $10,296 
           
Facility consolidation costs included in cost of sales   986    1,202 
           
Administrative consolidation costs included in other expense   98    1,231 
           
Legal costs included in other expense   —    544 
           
Total other expense   98    1,775 
           
Amortization of debt discount   1,113    — 
           
Unusual expense before income taxes   2,197    2,977 
           
Provision (benefit) for income taxes on unusual expenses   (801)   (1,072)
           
Net income before unusual items and amortization of debt discount  $10,076   $12,201 
           
           
Per share data:          
           
Reported net income          
Basic  $0.31   $0.36 
Diluted   0.30    0.36 
           
Net income before unusual items and amortization of debt discount          
Basic  $0.35   $0.43 
Diluted   0.35    0.43 

 

 

Management has provided the above reconciliation of net income before unusual items and amortization of debt discount as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section “Use of Non-GAAP Financial Measures” above. We have included the amortization of debt discount in our analysis in order to facilitate comparison with the non-GAAP earnings guidance provided in the “Outlook” section of this and previous releases which exclude such expense.

 

 

 

 

 

 

 
 

 

 

CONMED News Release Continued Page 9 of 13 July 26, 2012

 

CONMED CORPORATION

RECONCILIATION OF REPORTED NET INCOME TO NON-GAAP NET INCOME

BEFORE UNUSUAL ITEMS AND AMORTIZATION OF DEBT DISCOUNT

Six Months Ended June 30, 2011 and 2012

(in thousands except per share amounts)

(unaudited)

 

   2011  2012
       
Reported net income  $17,675   $20,264 
           
Facility consolidation costs included in cost of sales   1,740    2,676 
           
Administrative consolidation costs included in other expense   792    1,504 
           
Costs associated with purchase of Nordic region distributor   —    704 
           
Legal costs included in other expense   —    1,555 
           
Total other expense   792    3,763 
           
Amortization of debt discount   2,207    — 
           
Unusual expense before income taxes   4,739    6,439 
           
Provision (benefit) for income taxes on unusual expenses   (1,727)   (2,318)
           
Net income before unusual items and amortization of debt discount  $20,687   $24,385 
           
           
Per share data:          
           
Reported net income          
Basic  $0.62   $0.72 
Diluted   0.61    0.71 
           
Net income before unusual items and amortization of debt discount          
Basic  $0.73   $0.87 
Diluted   0.72    0.85 

  

Management has provided the above reconciliation of net income before unusual items and amortization of debt discount as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section “Use of Non-GAAP Financial Measures” above. We have included the amortization of debt discount in our analysis in order to facilitate comparison with the non-GAAP earnings guidance provided in the “Outlook” section of this and previous releases which exclude such expense.

 

 
 

 

CONMED News Release Continued Page 10 of 13 July 26, 2012

 

 

CONMED CORPORATION

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(in thousands)

(unaudited)

 

   Three months ended  Six months ended
   June 30,  June 30,
   2011  2012  2011  2012
             
             
Reported income from operations  $16,698   $17,058   $33,961   $34,080 
                     
Facility consolidation                    
costs included in cost of sales   986    1,202    1,740    2,676 
                     
Administrative consolidation                    
costs included in other expense   98    1,231    792    1,504 
                     
Costs associated with purchase                    
of Nordic region distributor   —    —    —    704 
                     
Legal costs included in other expense   —    544    —    1,555 
                     
Adjusted income from operations  $17,782   $20,035   $36,493   $40,519 
                     
Operating Margin                    
Reported (GAAP)   9.1%   9.0%   9.3%   8.9%
                     
Adjusted (Non-GAAP)   9.7%   10.6%   10.0%   10.6%

 

 

Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section “Use of Non-GAAP Financial Measures” above.

 

 
 

 

CONMED News Release Continued Page 11 of 13 July 26, 2012

 

CONMED CORPORATION

RECONCILIATION OF REPORTED NET INCOME TO EBITDA & ADJUSTED EBITDA

(in thousands)

(unaudited)

 

 

   Three months ended  Six months ended
   June 30,  June 30,
   2011  2012  2011  2012
             
Net Income  $8,680   $10,296   $17,675   $20,264 
                     
Provision for income taxes   5,198    5,211    10,567    10,828 
                     
Interest expense   1,707    1,551    3,512    2,988 
                     
Depreciation   4,567    4,586    8,983    9,274 
                     
Amortization of debt discount   1,113    —    2,207    — 
                     
Amortization, all other   4,719    6,459    9,240    13,423 
                     
EBITDA (using GAAP measures)  $25,984   $28,103   $52,184   $56,777 
                     
Facility consolidation                    
costs included in cost of sales   986    1,202    1,740    2,676 
                     
Administrative consolidation                    
costs included in other expense   98    1,231    792    1,504 
                     
Costs associated with purchase                    
of Nordic region distributor   —    —    —    704 
                     
Legal costs included in other expense   —    544    —    1,555 
                     
Adjusted EBITDA  $27,068   $31,080   $54,716   $63,216 
                     
EBITDA Margin                    
EBITDA (using GAAP measures)   14.2%   14.8%   14.2%   14.8%
Adjusted EBITDA                    
(using non-GAAP measures)   14.8%   16.4%   14.9%   16.5%

 

 

Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section “Use of Non-GAAP Financial Measures” above.

 

 
 

 

CONMED News Release Continued Page 12 of 13 July 26, 2012

 

CONMED CORPORATION

Second Quarter Sales Summary

 

 

   Three Months Ended June 30,
             
            Constant
            Currency
   2011  2012  Growth  Growth
   (in millions)      
Arthroscopy                    
Single-use  $57.0   $67.5    18.4%   18.6%
Capital   13.6    13.5    -0.7%   0.0%
    70.6    81.0    14.7%   15.0%
                     
Powered Surgical Instruments                    
Single-use   19.8    20.9    5.6%   5.9%
Capital   18.5    16.3    -11.9%   -11.7%
    38.3    37.2    -2.9%   -2.6%
                     
Electrosurgery                    
Single-use   18.1    18.4    1.7%   2.2%
Capital   8.0    6.0    -25.0%   -25.0%
    26.1    24.4    -6.5%   -6.1%
                     
Endoscopic Technologies                    
Single-use   12.5    13.3    6.4%   7.1%
Endosurgery                    
Single-use and reposable   19.1    18.2    -4.7%   -4.7%
Patient Care                    
Single-use   16.6    15.6    -6.0%   -6.6%
                     
Total                    
Single-use and reposable   143.1    153.9    7.5%   7.8%
Capital   40.1    35.8    -10.7%   -10.3%
   $183.2   $189.7    3.5%   3.8%
 
 

 

 

CONMED News Release Continued Page 13 of 13 July 26, 2012

 

CONMED CORPORATION

Six-Month Sales Summary

 

   Six Months Ended June 30,
             
            Constant
            Currency
   2011  2012  Growth  Growth
   (in millions)      
Arthroscopy                    
Single-use  $115.1   $136.7    18.8%   18.4%
Capital   30.9    30.5    -1.3%   -1.0%
    146.0    167.2    14.5%   14.3%
                     
Powered Surgical Instruments                    
Single-use   40.2    42.4    5.5%   5.4%
Capital   36.2    33.4    -7.7%   -7.9%
    76.4    75.8    -0.8%   -0.9%
                     
Electrosurgery                    
Single-use   34.8    35.0    0.6%   0.6%
Capital   14.9    11.9    -20.1%   -20.1%
    49.7    46.9    -5.6%   -5.6%
                     
Endoscopic Technologies                    
Single-use   24.4    26.2    7.4%   7.3%
Endosurgery                    
Single-use and reposable   37.0    36.3    -1.9%   -1.9%
Patient Care                    
Single-use   33.2    31.6    -4.8%   -5.1%
                     
Total                    
Single-use and reposable   284.7    308.2    8.3%   8.1%
Capital   82.0    75.8    -7.6%   -7.5%
   $366.7   $384.0    4.7%   4.6%